The choice of therapy in acromegaly. Results of treatment at a tertiary care hospital

Neuroendocrinology Letters

Volumn 29, Issue 6, 2008, Pages 1038-1044

  Isidro, Ma Luisa ^a   Castro, José Antonio ^a   Penín, Manuel ^a   Armenta, Jacinto ^a   Cordido, Fernando ^a,b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

Acromegaly; First line treatment; Somatostatin analogs; Surgery; Treatment

Indexed keywords

PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; MALE; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; TERTIARY HEALTH CARE; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; TUMOR VOLUME; VISION;

EID: 59849128206     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Bevan JS (2005). Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 90: 1856-1863.
2. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, et al (2002). Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 87: 4554-4563.
3. Bolanowski M, Bar-Andziak E, Kos-Kudła B, Krzyzanowska-Swiniarska B, Lewiński A, Łomna-Bogdanov E, et al (2008). Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs therapy in acromegaly. Neuro Endocrinol Lett. 29: 59-62.
4. Bolanowski M, Zatonska K, Kaluzny M, Zielinski G, Bednarek-Tupikowska G, Bohdanowicz-Pawlak A et al (2006). A follow-up of 130 patients with acromegaly in a single centre. Neuro Endocrinol Lett. 27: 828-832.
5. Bourdelot A, Coste J, Hazebroucq V, Gaillard S, Cazabat L, Bertagna X, et al (2004). Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. Eur J Endocrinol. 150: 763-771.
6. Burt MG, Ho KK (2006). Newer options in the management of acromegaly. Intern Med J. 36: 437-444.
7. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, et al (2003). Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab. 88: 4759-4767.
8. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, et al (2006b). Partial surgical removal of GH-secreting pituitary tumors enhances the response to somatostatin analogues in acromegaly. J Clin Endocrinol Metab. 91: 85-92.
9. Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E (2006a). First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest. 29: 1017-1020.
10. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, et al (2006c). Efficacy of 12-month treatment with the GM receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 154: 467-477.
11. Colao A, Pivonello R, Cappabianca P, Auriemma RS, De Martino MC, Ciccarelli A, et al (2003). The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. J Endocrinol Invest. 26 (10 Suppl):53-56.
12. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, et al (2003). Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?. J Clin Endocrinol Metab. 88:3090-3098.
13. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al (2006). Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 91: 1397-1403.
14. Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, et al (2005). Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic faliure?. Clin Endocrinol (Oxf). 62: 410-417.
15. De P, Rees DA, Davies N, John R, Neal, J, Mills RG, et al (2003). Transsphenoidal surgery for acromegaty in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab. 88: 3567-3572.
16. Erturk E, Tuncel E, Kiyici S, Ersoy C, Duran C, Imamoglu S (2005). Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience. Pituitary. 8: 93-97.
17. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005). Long acting somatostatin analog therapy of acromegaly. J Clin Endocrinol Metab. 90: 4465-4473.
18. Freda PU, Post KD, Powell JS, Wardlaw SL (1998). Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab. 83: 3808-3816.
19. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al (2000). Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 85: 526-529.
20. Gullu S, Keles H, Delibasi T, Tonyukuk V, Kamel N, Endorgan G (2004). Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol. 150: 465-471.
21. Jallad RS, Musolino NR, Salgado NR, Bronstein MD (2005). Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf). 63: 168-175.
22. Jenkins D, O'Brien I, Jonhson A, Shakespear R, Sheppard MC, Stewart PM (1995). The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf). 43: 517-522.
23. Lissett CA, Pearcey SR, Laing I, Tetlow L, Davis JR, Shalet SM (1998). The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf). 49: 653-657.
24. Lorenzo-Solar M, Castro A, Peino R, Fernandez-Alvarez J, Dieguez C, Casanueva FF (2005). Can treatment with somatostatin analogs replace neurosurgery?. J Endocrinol Invest. 28 (11 Suppl): 48-52.
25. Losa M, Martini P, Urbaz L, Ribotto P, Castrignano T, Giovanelli M. (2006). Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg. 104: 899-906.
26. Maison P, Tropeano AI, Macquin-Mavier I, Guistina A, Chanson P (2007). Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 92: 1743-1747.
27. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, et al (2005). Consensus statement: medical management of acromegaly. Eur J Endocrinol. 153: 737-740.
28. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman L, Grossman A, et al (2002). Guidelines for acromegaly management. J Clin Endocrinol Metab. 87: 4054-4058.
29. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, et al (2005). A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 90: 4405-4410.
30. Mestrón A, Webb SM, Astorga R, Benito P, Catalá M, Gaztambide S, et al (2004). Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol. 151: 439-446.
31. Newman C, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al (1998). Octreotide as a primary therapy for acromegaly. J Clin Endocrinol Metab. 83: 3034-3040.
32. Petersenn S (2005). Efficacy and limits of somatostatin analogs. J Endocrinol Invest. 28 (11 Suppl): 53-57.
33. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, et al (2005). Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 152: 61-66.
34. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, et al (2007). Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patients. J Clin Endocrinol Metab. 92: 1592-1599.
35. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, et al (2006). Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab. 91: 121-128.
36. Rudnik A, Kos-Kudła B, Larysz D, Zawadzki T, Bazowski P (2007). Endoscopic transsphenoidal treatment of hormonally active pituitary adenomas. Neuro Endocrinol Lett. 28: 438-444.
37. Serri O, Beauregard C, Hardy J (2004). Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegegaly. J Clin Endocrinol Metab. 89: 658-661.
38. Shalet SM (2004). Biochemical monitoring of disease activity after surgery for acromegaly. J Clin Endocrinol Metab. 89: 492-494.
39. Sheppard MC (2003). Primary medical therapy for acromegaly. Clin Endocrinol (Oxf). 58: 387-399.
40. Shimon I, Melmed S (1998). Management of pituitary tumors. Ann Intern Med. 129: 472-483.
41. Sze L, Schmid C, Bloch KE, Bernays R, Brandle M. (2007). Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol. 156: 321-329.
42. Trainer PJ (2003). Lessons from 6 years of GH receptor antagonist therapy for acromegaly. J Endocrinol Invest. 26 (10 Suppl): 44-52.
43. Turner HE, Thorton-Jones VA, Wass JA. (2004). Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf). 61: 224-231.
44. Wass J. (2005). Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues. Eur J Endocrinol. 152: 693-694.
45. Wilson LS, Shin JL, Ezzat S (2001). Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract. 7: 170-180.
46. Yamada S, Aiba T, Takada K, Ozawa Y, Shimizu T, Sawano S, et al (1996). Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome. Clin Endocrinol (Oxf). 45: 291-298.